This study investigates extrapulmonary neuroendocrine carcinoma. The purpose of this study is to evaluate the safety and effectiveness of an investigational medication in patients who have relapsed after initial treatment.
This study evaluates how the investigational medication works in targeting specific proteins that may be present in the cancer cells. It focuses on understanding the safety and potential benefits of this treatment for participants.
- Who can participate: Adults aged 19 and older with relapsed extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy can participate. Participants must have measurable disease and meet specific health criteria.
- Study details: Participants will receive the investigational medication through an IV infusion. There is no placebo used in this study. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine.
How understandable was the trial content above?
Hard to understand
Easy to understand